NL2014935B1 - T cell receptor like antibodies having fine specificity. - Google Patents

T cell receptor like antibodies having fine specificity. Download PDF

Info

Publication number
NL2014935B1
NL2014935B1 NL2014935A NL2014935A NL2014935B1 NL 2014935 B1 NL2014935 B1 NL 2014935B1 NL 2014935 A NL2014935 A NL 2014935A NL 2014935 A NL2014935 A NL 2014935A NL 2014935 B1 NL2014935 B1 NL 2014935B1
Authority
NL
Netherlands
Prior art keywords
antibody
hla
binding
peptide
amino acid
Prior art date
Application number
NL2014935A
Other languages
English (en)
Dutch (nl)
Other versions
NL2014935A (en
Inventor
Peled Kamar Mira
Denkberg Galit
Reiter Yoram
Beer Ilan
Sinik Keren
Teboul Yael (Elbaz)
Shperber Yael (Sery)
Erel Segal Reut
Original Assignee
Applied Immune Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL2014935A priority Critical patent/NL2014935B1/en
Application filed by Applied Immune Tech Ltd filed Critical Applied Immune Tech Ltd
Priority to SG10202007398PA priority patent/SG10202007398PA/en
Priority to PCT/IL2016/050600 priority patent/WO2016199141A2/en
Priority to EP16734763.2A priority patent/EP3302537A1/en
Priority to CN201680039192.4A priority patent/CN107847569A/zh
Priority to PCT/IL2016/050599 priority patent/WO2016199140A1/en
Priority to KR1020187000504A priority patent/KR20180012851A/ko
Priority to US15/579,616 priority patent/US11001642B2/en
Priority to MX2017015801A priority patent/MX394431B/es
Priority to MX2017015928A priority patent/MX2017015928A/es
Priority to IL256178A priority patent/IL256178B2/en
Priority to CN201680040163.XA priority patent/CN108025045B/zh
Priority to JP2017563331A priority patent/JP6912392B2/ja
Priority to JP2017563328A priority patent/JP7013243B2/ja
Priority to AU2016276556A priority patent/AU2016276556C1/en
Priority to EP16739266.1A priority patent/EP3302538B1/en
Priority to CN202210030010.4A priority patent/CN114437217B/zh
Priority to CA3220475A priority patent/CA3220475A1/en
Priority to CN202210349590.3A priority patent/CN114605547B/zh
Priority to ES16739266T priority patent/ES2922236T3/es
Priority to EP22154188.1A priority patent/EP4039270A1/en
Priority to KR1020177037826A priority patent/KR20180011275A/ko
Priority to EP24193198.9A priority patent/EP4488293A3/en
Priority to CA2987889A priority patent/CA2987889A1/en
Priority to CA2988270A priority patent/CA2988270A1/en
Priority to AU2016276555A priority patent/AU2016276555B2/en
Publication of NL2014935A publication Critical patent/NL2014935A/en
Application granted granted Critical
Publication of NL2014935B1 publication Critical patent/NL2014935B1/en
Priority to MX2022009493A priority patent/MX2022009493A/es
Priority to IL256177A priority patent/IL256177A/en
Priority to US17/317,824 priority patent/US12252547B2/en
Priority to JP2021113633A priority patent/JP7147018B2/ja
Priority to JP2022150286A priority patent/JP7376655B2/ja
Priority to AU2022268398A priority patent/AU2022268398A1/en
Priority to IL304821A priority patent/IL304821A/en
Priority to JP2023183842A priority patent/JP2024016092A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL2014935A 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity. NL2014935B1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.
PCT/IL2016/050600 WO2016199141A2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP16734763.2A EP3302537A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
CN201680039192.4A CN107847569A (zh) 2015-06-08 2016-06-08 具有优良特异性的类t细胞受体抗体
PCT/IL2016/050599 WO2016199140A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
KR1020187000504A KR20180012851A (ko) 2015-06-08 2016-06-08 고 친화성 및 고 특이성을 가진 tcr-유사 항체 결합 도메인을 포함하는 친화성 엔티티 및 이의 용도
US15/579,616 US11001642B2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
MX2017015801A MX394431B (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
MX2017015928A MX2017015928A (es) 2015-06-08 2016-06-08 Anticuerpos similares al receptor de celulas t que tienen una especificidad fina.
IL256178A IL256178B2 (en) 2015-06-08 2016-06-08 Entities with high affinity and fine binding specificity containing binding regions of T-cell receptor-like antibodies and their uses
CN201680040163.XA CN108025045B (zh) 2015-06-08 2016-06-08 具有高亲和性和优良特异性的类tcr抗体结合域的亲和性实体及其用途
JP2017563331A JP6912392B2 (ja) 2015-06-08 2016-06-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
JP2017563328A JP7013243B2 (ja) 2015-06-08 2016-06-08 微細特異性を有する親和性結合体
AU2016276556A AU2016276556C1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
EP16739266.1A EP3302538B1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CN202210030010.4A CN114437217B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
SG10202007398PA SG10202007398PA (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CA3220475A CA3220475A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CN202210349590.3A CN114605547B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
EP22154188.1A EP4039270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
KR1020177037826A KR20180011275A (ko) 2015-06-08 2016-06-08 우수한 특이성을 가진 t 세포 수용체 유사 항체
EP24193198.9A EP4488293A3 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CA2987889A CA2987889A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
CA2988270A CA2988270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
AU2016276555A AU2016276555B2 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
ES16739266T ES2922236T3 (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión a anticuerpo similar a TCR con gran afinidad y buena especificidad y usos de las mismas
MX2022009493A MX2022009493A (es) 2015-06-08 2017-12-06 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
IL256177A IL256177A (en) 2015-06-08 2017-12-07 T-cell receptor-like antibodies with subtle specificity
US17/317,824 US12252547B2 (en) 2015-06-08 2021-05-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
JP2021113633A JP7147018B2 (ja) 2015-06-08 2021-07-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
JP2022150286A JP7376655B2 (ja) 2015-06-08 2022-09-21 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
AU2022268398A AU2022268398A1 (en) 2015-06-08 2022-11-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
IL304821A IL304821A (en) 2015-06-08 2023-07-30 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
JP2023183842A JP2024016092A (ja) 2015-06-08 2023-10-26 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Publications (2)

Publication Number Publication Date
NL2014935A NL2014935A (en) 2016-12-12
NL2014935B1 true NL2014935B1 (en) 2017-02-03

Family

ID=54325627

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Country Status (13)

Country Link
US (2) US11001642B2 (enExample)
EP (4) EP3302537A1 (enExample)
JP (5) JP6912392B2 (enExample)
KR (2) KR20180011275A (enExample)
CN (4) CN114605547B (enExample)
AU (3) AU2016276555B2 (enExample)
CA (3) CA2988270A1 (enExample)
ES (1) ES2922236T3 (enExample)
IL (3) IL256178B2 (enExample)
MX (3) MX2017015928A (enExample)
NL (1) NL2014935B1 (enExample)
SG (1) SG10202007398PA (enExample)
WO (2) WO2016199140A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA45004A (fr) * 2015-10-09 2019-03-27 Immatics Biotechnologies Gmbh Anticorps spécifiques anti-wt1-hla
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
JP7303750B2 (ja) * 2017-01-24 2023-07-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
WO2018200585A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
EP3635000A4 (en) * 2017-05-16 2021-04-14 The Johns Hopkins University Manabodies and methods of using
JP2020523985A (ja) * 2017-05-31 2020-08-13 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． 細胞免疫治療の組成物及び方法
ES2991091T3 (es) * 2017-06-05 2024-12-02 Univ Mie Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4
MX2019015053A (es) * 2017-06-14 2020-02-13 Adicet Bio Inc Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN111527107B (zh) * 2017-12-21 2024-10-01 豪夫迈·罗氏有限公司 结合hla-a2/wt1的抗体
US20200399377A1 (en) * 2018-02-23 2020-12-24 Abexxa Biologics Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
GB201803750D0 (en) * 2018-03-08 2018-04-25 Immunocore Ltd Method
CN112424601A (zh) * 2018-04-04 2021-02-26 豪夫迈·罗氏有限公司 检测癌症患者中肿瘤抗原的诊断性测定法
JP2021528382A (ja) * 2018-06-04 2021-10-21 エーピーオー‐ティー ビー．ヴイ． 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
US11939381B2 (en) * 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
KR20210087458A (ko) 2018-10-01 2021-07-12 아디셋 바이오, 인크. 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
EA202190926A1 (ru) 2018-10-01 2021-06-25 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
KR20210134091A (ko) * 2019-01-29 2021-11-08 그릿스톤 바이오, 인코포레이티드 다중특이적 결합 단백질
WO2020194195A1 (en) * 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
WO2020257288A2 (en) * 2019-06-18 2020-12-24 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
CN114174345B (zh) * 2019-07-24 2024-11-26 瑞泽恩制药公司 具有mage-a4特异性的嵌合抗原受体和其用途
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CN110563804A (zh) * 2019-09-19 2019-12-13 河南省农业科学院 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
PE20221282A1 (es) * 2019-12-18 2022-09-05 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
MX2022013898A (es) 2020-05-05 2023-02-09 Regeneron Pharma Car que comprende cd28 zeta y cd3 zeta.
JP2023527293A (ja) * 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
EP4304725A1 (en) * 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
JP2024509910A (ja) 2021-03-09 2024-03-05 シーディアール－ライフ・アクチェンゲゼルシャフト Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質
AU2022271212A1 (en) * 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2024546589A (ja) * 2021-12-14 2024-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４×ｃｄ３二重特異性抗体及び４－１ｂｂ（ｃｄ１３７）アゴニストを使用したがんの治療
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
TW202513802A (zh) * 2023-09-22 2025-04-01 美商再生元醫藥公司 獲得與多肽－ｍｈｃ界面結合的抗體分子之方法
GB202315181D0 (en) * 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US8258260B2 (en) 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
EP0857176A1 (en) 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070099182A1 (en) 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7488793B2 (en) 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
DE602005011617D1 (de) 2004-05-19 2009-01-22 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
US20100068186A1 (en) 2004-05-26 2010-03-18 Avidex Limited High affinity telomerase t cell receptors
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US8378074B2 (en) 2005-04-01 2013-02-19 Immunocore Limited High affinity HIV T cell receptors
EP1717245B1 (en) 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
PL1760088T3 (pl) 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
CA2630023A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
WO2007143104A2 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20100158927A1 (en) 2007-03-29 2010-06-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
BRPI0813621A2 (pt) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
CN105566450A (zh) 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 免疫疗法的新型免疫抗原表位
WO2009026117A2 (en) 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
JP2012521761A (ja) 2009-03-25 2012-09-20 アルター・バイオサイエンス・コーポレーション Ｈｉｖｖｐｒ−特異的ｔ細胞受容体
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CN102812043A (zh) 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
CA2798120A1 (en) * 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
EP3778642A1 (en) * 2010-12-27 2021-02-17 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
CA2826942C (en) 2011-02-11 2021-08-03 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
JP6082997B2 (ja) * 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
EP3066131A1 (en) 2013-11-07 2016-09-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
KR102721595B1 (ko) 2015-04-03 2024-10-23 유레카 쎄라퓨틱스, 인코포레이티드 Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
MX2019015053A (es) 2017-06-14 2020-02-13 Adicet Bio Inc Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.

Also Published As

Publication number Publication date
JP2018526970A (ja) 2018-09-20
US20180171024A1 (en) 2018-06-21
US11001642B2 (en) 2021-05-11
IL256178A (en) 2018-02-28
US20210388111A1 (en) 2021-12-16
EP3302538A2 (en) 2018-04-11
JP7376655B2 (ja) 2023-11-08
JP2022188107A (ja) 2022-12-20
JP6912392B2 (ja) 2021-08-04
AU2016276555B2 (en) 2022-07-21
MX2017015928A (es) 2018-06-22
CN107847569A (zh) 2018-03-27
KR20180012851A (ko) 2018-02-06
EP4488293A3 (en) 2025-03-26
CN108025045B (zh) 2022-04-26
KR20180011275A (ko) 2018-01-31
AU2016276556B2 (en) 2022-08-11
AU2016276556C1 (en) 2023-01-19
ES2922236T3 (es) 2022-09-12
EP4039270A9 (en) 2023-03-22
JP2021176861A (ja) 2021-11-11
CA2988270A1 (en) 2016-12-15
NL2014935A (en) 2016-12-12
WO2016199141A2 (en) 2016-12-15
IL304821A (en) 2023-09-01
CN114605547B (zh) 2025-02-25
CN114605547A (zh) 2022-06-10
EP3302538B1 (en) 2022-02-09
JP2024016092A (ja) 2024-02-06
SG10202007398PA (en) 2020-09-29
EP4039270A1 (en) 2022-08-10
IL256177A (en) 2018-02-28
US12252547B2 (en) 2025-03-18
WO2016199141A8 (en) 2017-11-16
WO2016199140A1 (en) 2016-12-15
IL256178B2 (en) 2024-01-01
CN114437217A (zh) 2022-05-06
IL256178B1 (en) 2023-09-01
JP7147018B2 (ja) 2022-10-04
MX2017015801A (es) 2018-08-01
MX394431B (es) 2025-03-24
EP4488293A2 (en) 2025-01-08
CA2987889A1 (en) 2016-12-15
AU2022268398A1 (en) 2022-12-15
WO2016199140A8 (en) 2016-12-29
EP3302537A1 (en) 2018-04-11
CN114437217B (zh) 2025-03-14
WO2016199141A3 (en) 2017-01-19
JP7013243B2 (ja) 2022-01-31
AU2016276555A1 (en) 2018-01-18
JP2018527884A (ja) 2018-09-27
CA3220475A1 (en) 2016-12-15
AU2016276556A1 (en) 2018-01-18
MX2022009493A (es) 2022-12-13
CN108025045A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
NL2014935B1 (en) T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) T cell receptor like antibodies having fine specificity
CN106632677B (zh) 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
Dahan et al. T-cell-receptor-like antibodies–generation, function and applications
JP7282760B2 (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US20100158927A1 (en) Antibodies, methods and kits for diagnosing and treating melanoma
HK1248255A1 (zh) 靶向ny-eso-1肽/mhc复合物的构建体及其用途
HK40069173A (en) Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2024178334A1 (en) Improved phox2b pc-car generation based on structure and saturation mutagenesis